Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.64 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.64 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 3/20 | 0.60 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.60 |
| ▸ | GUSB | P08236 | 1/20 | 0.60 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 4/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4857648 | 0.88 | MEN1 (0.67) | NR4A1NR4A2NR4A3MAOBPARP10 | |
| SCHEMBL7368121 | 0.85 | GUSB (0.64) | NR4A1NR4A2NR4A3MAOBPARP10 | |
| SCHEMBL1416849 | 0.85 | NR4A2 (0.68) | NR4A2MAOBGUSBSRD5A2ALDH1A1 | |
| SCHEMBL978700 | 0.81 | NR4A2 (0.68) | NR4A1NR4A2NR4A3MAOBPARP10 | |
| SCHEMBL1960673 | 0.81 | NR4A1 (0.72) | NR4A1NR4A2NR4A3MAOBPARP10 | |
| SCHEMBL4220632 | 0.81 | NR4A1 (0.72) | NR4A1NR4A2NR4A3MAOBPARP10 | |
| SCHEMBL3580785 | 0.81 | ERCC5 (0.58) | PARP10SRD5A2MAPTSMN1; SMN2 | |
| SCHEMBL2686570 | 0.80 | NR4A1 (0.70) | NR4A1NR4A2NR4A3MAOBPARP10 | |
| SCHEMBL41220 | 0.80 | NR4A1 (0.70) | NR4A1NR4A2NR4A3MAOBPARP10 | |
| SCHEMBL9718167 | 0.80 | NR4A1 (0.70) | NR4A1NR4A2NR4A3MAOBPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20210187108-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2021-06-24 | — | — | US | disclosed |
| CN-108329246-B | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TRKA kinase inhibitors | 阵列生物制药公司 | 2021-02-26 | — | — | CN | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10772962-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | ARVINAS OPERATIONS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180334450-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-9981959-B2 | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-05-29 | — | — | US | disclosed |
| WO-2014078331-A1 | N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2012158413-A2 | PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20080287517-A1 | Pyrazole Derivatives as Cb1 Modulators | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1910331-A1 | PYRAZOLE DERIVATIVES AS CBl MODULATORS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010217-A1 | PYRAZOLE DERIVATIVES AS CBl MODULATORS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
| EP-1077956-B1 | 3-SUBSTITUTED 5-ARYL-4-ISOXAZOLECARBONITRILES HAVING ANTIVIRAL ACTIVITY | UNIV CATANIA (IT) | 2004-10-13 | — | — | EP | disclosed |
| US-6414004-B1 | POLIO VIRUS, ECHOVIRUS, COXSACKLE VIRUS, RHINO VIRUS, MYXOVIRUS | UNIVERSITA' DEGLI STUDI DI CATANIA (IT) | 2002-07-02 | — | — | US | disclosed |
| EP-1077956-A1 | 3-SUBSTITUTED 5-ARYL-4-ISOXAZOLECARBONITRILES HAVING ANTIVIRAL ACTIVITY | Universita' Degli Studi Di Catania (IT) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059984-A1 | 3-SUBSTITUTED 5-ARYL-4-ISOXAZOLECARBONITRILES HAVING ANTIVIRAL ACTIVITY | UNIVERSITA' DEGLI STUDI DI CATANIA (IT) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | NR4A1 1015/4885NR4A2 1967/4885NR4A3 2160/4885 |
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | DPYD, TYMP, ABCB1 | NR4A1 4169/4885NR4A2 3518/4885NR4A3 3819/4885 |
| US-10772962-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | BRPF3, STUB1, BRDT | NR4A1 3725/4885NR4A2 2409/4885NR4A3 2014/4885 |
| US-20080287517-A1 | Pyrazole Derivatives as Cb1 Modulators | CNR1, CNR2, HTR3C | NR4A1 207/4885NR4A2 632/4885NR4A3 238/4885 |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | RET, TK1, DSTYK | NR4A1 738/4885NR4A2 1300/4885NR4A3 1260/4885 |
| US-20210187108-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | NR4A1 3725/4885NR4A2 2409/4885NR4A3 2014/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | NR4A1 1015/4885NR4A2 1967/4885NR4A3 2160/4885 |
| US-20180334450-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | RET, TK1, DSTYK | NR4A1 738/4885NR4A2 1300/4885NR4A3 1260/4885 |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | NR4A1 3725/4885NR4A2 2409/4885NR4A3 2014/4885 |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | NR4A1 1015/4885NR4A2 1967/4885NR4A3 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.